Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Aya Jakobovits

Adicet Bio, Inc.

Acerta Pharma, an affiliate of AstraZeneca, develops and delivers targeted novel transformational medicines for patients with hematological malignancies.  Acerta Pharma uses innovative approaches to discover, develop, and deliver targeted medicines, focusing on innovative clinical strategies and resistance biology.

Acerta Pharma

At Adicet (Nasdaq: ACET), we are defined by our mission to deliver best-in-class gamma-delta T cell therapies for patients fighting cancer. Every one of our team members, whether in the lab, manufacturing, or general business role, comes to work every day with the patient in mind. 
 
As pioneers in the cell therapy space, we are honored and humbled by the opportunity to put our talents to bear in developing transformative therapies to defeat cancer. We believe that the best way to do this is through discovering and developing allogeneic gamma-delta T cell therapies, a novel type of cell therapy.
 
Adicet has chosen the gamma-delta T cell because it has multiple ways to target and kill cancer cells, which may provide a better chance of achieving complete and durable responses to therapy. Additionally, instead of using cells from the already sick cancer patient, Adicet uses cells from unrelated donors (allogeneic) because they are reliable and readily available allowing us to rapidly and cost-effectively scale production of these medicines and make them available when needed (“off-the-shelf”).
 
Specifically, as a clinical stage biotechnology company we are advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL) to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. 
  
To learn more or inquire about joining our team in Boston, MA or Redwood City, CA, please visit http://www.adicetbio.com

Novartis Venture Fund

OrbiMed

Pontifax

aMoon2 Fund

Samsung Ventures

Johnson & Johnson Robotics and Digital Solutions

Regeneron

Adicet Bio, Inc

Adicet is pleased to welcome to the team our new Vice President of Clinical Development, Dr. Benjamin Hsu!
 
As Adicet builds out our pipeline, applying our novel allogeneic gamma delta CAR T cell platform to the autoimmune space, Ben will lead the design and execution of the clinical development plan for Adicet’s autoimmune programs.
 
Ben brings more than 20 years of experience in the biotech and pharmaceutical industry with extensive expertise in immunology and rheumatology clinical development. 
 
We are inspired by his enthusiasm to help advance our mission to deliver best-in-class gamma delta T cell therapies for patients fighting autoimmune diseases and cancer. 
 
#celltherapy #biotechnology #gammadelta #CART #autoimmune #autoimmunediseases #cancer #oncology #rarediseases #leadership #executiveleadership

Adicet is pleased to shine a light on #RareDiseaseDay 2024!
 
This global movement is significant because #rarediseases, while individually uncommon, collectively affect millions of people worldwide. In many cases, rare diseases are severe, chronic and life-threatening. Due to their rarity, the conditions often result in challenges such as delayed diagnosis, a lack of medical expertise and few treatment options.
 
Adicet is honored to dedicate our team’s expertise to advancing #clinicaltrials and developing potential therapeutic options for patients with rare #autoimmune diseases like #lupusnephritis and rare #bloodcancers including MCL (mantle cell lymphoma).
 
Today and every day we stand with the #patients and #healthcare providers fighting these rare diseases.
 
#ShowYourStripes #ShareYourColours #rarediseaseawareness #NORD #CareAboutRare #GlobalGenes #ActRare2024 #LightUpForRare #EURODIS #PatientAdvocacy

Don’t miss our Chief Scientific Officer, Blake Aftab at #IO360 2024!

He’s speaking among other thought leaders in the space regarding Expanding a CAR Gamma Delta T Cell Pipeline in Autoimmune Diseases and Oncology!

They’ll explore how this novel platform has applicability across indications to serve more patients in need of transformative therapies.

#IO360NYC #ImmunoOncology #Autoimmune #AutoimmuneDiseases #Oncology #Cancer #GammaDeltaTCells #Leadership #Innovation #Biotechnology #Biotech

As conference Chair, Adicet Bio, Inc’s Chief Scientific Officer, Blake Aftab, helps kick off the 3rd Annual European Allogeneic Cell Therapies Summit with the Industry Leaders Fireside Chat reviewing the latest hurdles and highlights in the #allogeneic #celltherapy field! 
 
Among other C-suite thought leaders, Blake will also co-lead a session exploring the exciting clinical advancements and investment opportunities in allogeneic drug development. 
 
Check out the full schedule here: https://lnkd.in/deK99dUH
 
#biotechnology #CART #TCellRx #biotechtrends #industrycollaboration #leadership

Adicet’s VP and Head of Clinical Operations, Ekatherina Goryachikov, joins top industry experts at Advanced Therapies Week to review best practices in designing and running CAR T clinical trials that help advance the cell therapy space for patients.
 
#celltherapy #clinicaltrials #TCellRx #biotechnology #leadership #ATW24 #AdvancedTherapies #IndustryEvolution

Adicet is pleased to welcome to the team our new Vice President of Clinical Development, Greg Vosganian, MD!
 
Greg brings with him more than a decade of experience in all stages of biopharmaceutical development during which time he has served as the Medical Director and Head of Clinical Development for several flagship biopharma companies.  
 
As a leader at Adicet, Greg will help drive program and clinical development strategies across our robust pipeline to advance our mission to deliver best-in-class gamma delta T cell therapies for patients. 
 
#celltherapy #biotechnology #gammadelta #leadership #executiveleadership

Adicet is pleased to announce today that based on ADI-001's clinical data to-date and its therapeutic potential in B-cell mediated diseases, we have decided to broaden its development to autoimmune diseases.     
 
The U.S. FDA recently cleared the IND for ADI-001 in lupus nephritis and we plan to initiate this clinical study in the upcoming second quarter. In addition to initiating development in lupus nephritis, we plan to expand the program in the near-term to additional autoimmune indications.   
 
Many thanks to our wonderful team who is inspired by our mission to deliver best-in-class gamma delta T cell therapies to patients fighting cancer and autoimmune diseases. 
 
#celltherapy #gammadelta #biotechnology #oncology #autoimmune

Don’t miss Adicet’s Chief Scientific Officer, Blake Aftab, who’s an invited presenter at the Opening Plenary Session of the International Society for Cell & Gene Therapy (ISCT) North American Conference today!
 
Alongside leaders in cell therapy development, Blake will review the current state of the field including Adicet’s progress in the clinic to date + the science driving our additional pipeline candidates tailored to address solid tumors. 
 
We’re inspired by all of the work being done across the cell therapy space in our shared vision to defeat cancer!
 
#cancer #oncology #celltherapy #cancerimmunotherapy #TCellRX #biotechnology #ISCTNA2023

We’re excited for Adicet’s VP and Head of Clinical Operations to serve as a speaker, moderator and participant on panels at the 8th #CARTCR Summit this week!

Along with other experts, Ekatherina, will help drive dialogue to advance innovation, solve challenges, enhance processes and elevate teams in the rapidly evolving space of cell therapy clinical trials.

Check out the full agenda here: https://ter.li/ho8ngg
 
#cancer #oncology #celltherapy #clinicaltrials #cancerimmunotherapy #TCellRX #biotechnology

Excited to see our VP of Nonclinical Development, Shon Green, Chair the flagship Focus Day session at the 8th #CARTCR Summit in Boston today!

She will lead a discussion among top experts in the cell therapy field reviewing next generation approaches to address solid tumors.

Check out the full agenda here: https://ter.li/ho8ngg
 
#cancer #oncology #celltherapy #cancerimmunotherapy #TCellRX #biotechnology

Metric
Company Name	Adicet Bio, Inc.	Acerta Pharma
Symbol	ACET
MSH ID	COM:ADICETBIO	COM:ACERTA-PHARMA
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Pharmaceutical
Country	US	NL
Stage
Employee Count	143
Website	adicetbio.com	acerta-pharma.com
LinkedIn	adicet-bio-inc
Founders

Metric
Market Cap	104.36M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ADICETBIO

Adicet Bio

Last Close

0.91

22/11 21:00

Market Cap

104.36M

Beta: -

Volume Today

1.17M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue